I-Tirzepatide Lyophilized High Purity 99% Peptide Powder 60mg ngebhodlela ngayinye yesifo sikashukela nokuncipha kwesisindo

I-Tirzepatide Lyophilized Powder (60 mg)

I-Tirzepatide (LY3298176) iyi-agonist yokuqala esebenza kabili eqondise kokubili i-GIP (i-insulinotropic polypeptide encike kuglucose) kanye ne-GLP-1 (i-glucagon-like peptide-1) receptors. Ithole imvume ye-US FDA ngoMeyi 2022 yokwelashwa kohlobo 2 lwesifo sikashukela i-mellitus (T2DM) njengesengezo ekudleni nasekuzivocavoceni.
Lo mkhiqizo unikezwa njengempushana oyinyumba engama-60mg e-lyophilized (eqandisiwe) ezitsheni, okumele ihlanganiswe kabusha namanzi e-bacteriostatic ngaphambi kokusetshenziswa. Uma iqhathaniswa ne-single GLP-1 receptor agonists njenge-semaglutide noma dulaglutide, i-tirzepatide ibonisa ukusebenza kahle okuphakeme ekuthuthukiseni ukulawulwa kwe-glucose yegazi, ukuthuthukisa ukuzwela kwe-insulin, kanye nokusekela ukwehla kwesisindo esikhulu. Lezi zinzuzo zidalulwe endleleni yayo yokusebenza ye-dual-receptor synergistic.

Izinzuzo Eziyinhloko
Ukulawula I-Glycemic

• Ivuselela ukukhiqizwa kwe-insulin ngendlela encike ku-glucose
• Yehlisa ukukhiqizwa kwe-glucagon, yehlisa ngempumelelo amazinga kashukela egazini
• Ilingisa imiphumela ehlanganisiwe ye-metabolic yakho kokubili i-GIP ne-GLP-1

Ukuphathwa Kwesisindo

• Ikhuthaza ukusutha futhi inciphisa ukudla kwe-caloric
• Kuboniswe ukwehla kwesisindo okunamandla nokuqhubekayo ezifundweni zomtholampilo

Impilo Yenhliziyo

• Idatha yokuqala ikhombisa ukwehla kwengozi yenhliziyo nemithambo yegazi ezigulini ezine-T2DM

Ukusetshenziswa kanye Nesilinganiso

• I-Tirzepatide lyophilized powder (60 mg) kufanele ihlanganiswe namanzi e-bacteriostatic ngaphambi kokusetshenziswa. Ukuphatha kwenziwa ngomjovo ongaphansi kwesikhumba, ngokuvamile kanye ngesonto ngosuku olufanayo isonto ngalinye.

Isifo sikashukela sohlobo 2

• Umthamo wokuqala: 2.5 mg kanye ngesonto
• I-Titration: Nyusa njalo emavikini angu-4 njengoba kubekezelelwe
• (→ 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg → 20 mg → 30 mg → 45 mg → kufika ku-60 mg)
• Umthamo Ojwayelekile: 10–30 mg masonto onke
• Umthamo omkhulu: 60 mg ngesonto

Ukukhuluphala / Ukulawulwa Kwesisindo

• Umthamo wokuqala: 2.5 mg kanye ngesonto
• I-Titration: Ukwenyuka komthamo kancane kancane njengoba kubekezelelwe
• (2.5 → 5 → 7.5 → 10 → 12.5 → 15 → 20 → 30 → 45 → 60 mg)
• Umthamo Ojwayelekile: 30-60 mg masonto onke
• Umthamo omkhulu: 60 mg ngesonto

Ukuqhathaniswa Kwesilinganiso Esinconyiwe

Qaphela:Qinisekisa ukuthi umthamo wangaphambilini ubekezelelwa kahle ngaphambi kokwenyuka.

Ukusabela Okubi Okungenzeka

• I-Gastrointestinal: Isicanucanu, ukuhlanza, isifo sohudo, nokungakhululeki kwesisu (imvamisa ngesikhathi sokuthwasa)
• I-Hypoglycemia: Ingozi ngokuvamile iphansi, kodwa iyanda lapho ihlanganiswa neminye imithi ye-antidiabetic
• Ukusabela Kwesayithi Lomjovo: Ububomvu, ukulunywa, ukuvuvukala, noma ubuhlungu obuncane endaweni
• I-pancreatitis: Akuvamile kodwa kungenzeka; qapha ubuhlungu besisu obuqhubekayo
• Imiphumela Yezinso: Ukuqapha ukusebenza kwezinso kungase kudingeke kubantu abathile

I-Pharmacokinetics

• Ingxenye Yempilo: Cishe iviki elingu-1
• I-Dosing Frequency: Isekela ukuphathwa okulula kanye ngesonto

Isifinyezo
I-Tirzepatide engu-60 mg i-lyophilized powder imelela intuthuko yokwelapha yesizukulwane esilandelayo, ehlanganisa ukulawula okunamandla kwe-glycemic nokusebenza okuphawulekayo kokwehla kwesisindo kanye nokuvikelwa okungenzeka kwenhliziyo nemithambo yegazi.
Ngeshejuli ye-titration kancane kancane (2.5 mg → kufika ku-60 mg), ivumela ukubekezelelana okuthuthukisiwe nokuguquguquka kokwelashwa komuntu ngamunye. Ukuphatha kwayo kanye ngesonto kuthuthukisa ukubambelela, kukwenze kube inketho entsha nephumelelayo yokuphatha uhlobo lwesifo sikashukela sohlobo 2 nokukhuluphala emitholampilo nasezilungiselelweni zocwaningo ezithuthukile.